Design of a Potential Colonic Drug Delivery System of Mesalamine

REFERENCES

• M Saffarin, GS Kumar, C Savariar, CJ Burnham, F Williams, and DC Neckers. (1986). A new approach to the oral administration of insulin and other peptide drugs. Science. 233 (4768):1081–1084.
   PubMedGoogle Scholar
• M Ashord, JT Fell, D Attwood, and PJ Woodhead. (1993). An in vitro investigation into the suitability of pH dependent polymers for colon targeting. Int J Pharm. 91 (2–3):241–245.
   Google Scholar
• VK Gupta, TE Beckert, and JC Price. (2001). A novel pH and time based multi unit potential colonic drug delivery system I development. Int J Pharm. 213 (1–2):83–91.
   PubMedGoogle Scholar
• Controlled Drug Delivery-Concepts and Advances S.P. Vyas, and R.K. Khar. Vallabh Prakashan, New Delhi, (2002)218–256.
   Google Scholar
• F Pozzi, P Furlani, A Gazzaniga, SS Davis, and IR Wilding. (1994). The time-clock system: a new oral dosage form for fast and complete release of drug after predetermined lag time. J Control Release 31 (1):99–108.
   Google Scholar
• KP Steed, G Hooper, N Monti, S Benedetti, G Fornasini, and IR Wilding. (1997). The use of pharacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“time clock” system). J Control Release 49 (2–3):115–122.
   Google Scholar
• MZI Khan, Z Prebeg, and N Kurjakovic. (1999). A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers, I: manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J Control Release 58 (2):215–222.
   PubMedGoogle Scholar
• YSR Krishnaiah, S Satyanarayan, and YU Rama Prasad. (1999). Studies of guar gum compression coated 5-aminosalicylic acid tablets for colon specific drug delivery. Drug Dev Ind Pharm 25 (5):651–657.
   PubMedGoogle Scholar
• SF Ahrabi, G Madsen, K Dyrstad, SA Sande, and C Graffner. (2000). Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 10 (1):53–52.
   PubMedGoogle Scholar
• CS Leopold, and D Eikeler. (2000). Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm 26 (12):1239–1246.
   PubMedGoogle Scholar
• CV Raghavan, C Muthulingam, JAJ Jeneta, and KR Thengungal. (2002). An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem Pharm Bull 50 (7):892–895.
   PubMed Web of Science ®Google Scholar
• ThF Vandamne, A Lenourry, C Charrueau, and JC Chameil. (2002). The use of polysaccharides to target drugs to the colon. Carbohydrate Polymers 48 (3):219–231.
   Google Scholar
• MK Chourasia, and SK Jain. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6 (1):33–66.
   PubMed Web of Science ®Google Scholar
• L Liu, L Fishman, J Kost, and KB Hicks. (2003). Pectin based systems for colon specific drug delivery via oral route. Biomaterials 24 (19):3333–3343.
   PubMed Web of Science ®Google Scholar
• DR Friend. (2005). New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57 (2):247–265.
   PubMed Web of Science ®Google Scholar
• G Rai, SK Jain, S Agrawal, S Bhadra, SS Pancholi, and GP Agrawal. (2005). Chitosan hydrochloride based microspheres of albendazole for colonic drug delivery. Pharmazie 60 (2):131–134.
   PubMedGoogle Scholar
• Lerner EI, Flashner M, Penhasi A. Gastointestinal drug delivery system, US patent 5,840,332, (1998).
   Google Scholar
• H. Schroder, and DE Campbell. (1972). Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13 (4):539–551.
   PubMedGoogle Scholar
• JN Healey. (1990). Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. J Gastroenterol Suppl 172:47–51.
   Google Scholar
• L Yang, JS Chu, and JA Fix. (2002). Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 235 (1–2):1–15.
   PubMedGoogle Scholar
• A Basit, and J Bloor. (2003). Perspectives on colonic drug delivery. Business Briefing: PharmaTech 185–190.
   Google Scholar
• BN Singh, and KH Kim. Drug delivery-oral route Encyclopedia of pharmaceutical Technology J. Swarbrick, and J. C. Boylan. Marcel Dekker, New York, (2002)886–909.
   Google Scholar
• H Brondsted, C Andersen, and L. Hovgaard. (1998). Crosslinked dextran—a new capsule material for colon targeting of drugs. J Control Release. 53 (1–3):7–13.
   PubMedGoogle Scholar
• YR Mahida, CE Lamming, A Gallagher, AB Hawthorne, and CJ Hawkey. (1991). 5-aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 32 (1):50–54.
   PubMedGoogle Scholar
• F Cominelli, CC Nast, A Duchini, and M. Lee. (1992). Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 103 (1):65–71.
   PubMedGoogle Scholar
• D Rachmilewitz, F Karmeli, LW Schwartz, and PL Simon. (1992). Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut. 33 (7):929–932.
   PubMedGoogle Scholar
• HO Collier, AA Francis, WJ McDonald-Gibson, and SA Saeed. (1976). Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins. 11 (2):219–225.
   PubMedGoogle Scholar
• P Sharon, M Ligumsky, D Rachmilewitz, and U. Zor. (1978). Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 75 (4):638–640.
   PubMedGoogle Scholar
• H Nahor, N Chell, H Kamyar, and et al. (2006). A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems. J Control Release. 110 (2):314–322.
   PubMedGoogle Scholar
• L François, C Louis, and T. Roch. (2002). New methods characterizing avalanche behavior to determine powder flow. Pharm Res. 19 (66):887–893.
   PubMedGoogle Scholar
• United States Pharmacopeia XXIX, NF XIV, United States Pharmacopeial Convention, Inc, Pharmaceutics. The Science of Dosage Form Design2nd M.E. Aulton. Churchill Livingstone, London, (2002)197–210.
   Google Scholar
• S. John. Powder flow Pharmaceutics: The Science of Dosage Form Design2nd ME Aulton. Churchill Livingstone, London, (2002)197–210.
   Google Scholar
• R Markus, K Sandra, B Thomas, P Hans-Ulrich, and D. Jennifer. (2001). A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 51 (3):183–190.
   PubMedGoogle Scholar
• ME Sangalli, A Maroni, A Foppoli, L Zema, F Giordano, and A. Gazzaniga. (2004). Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances. Eur J Pharm Sci. 22 (5):469–476.
   PubMedGoogle Scholar
• T Sawada, K Sako, M Fukui, S Yokohama, and M. Hayashi. (2003). A new index, the core erosion ratio, of compression coated rimed release tablets predicts the bioavailability of acetaminophen. Int J Pharm. 265 (1–2):55–63.
   PubMedGoogle Scholar
• IS Ahmed. (2005). Effect of simulated gastrointestinal conditions on drug release from pectin or ethyl cellulose as film coating for drug delivery to the colon. Drug Dev Ind Pharm. 31 (4–5):465–470.
   PubMedGoogle Scholar
• British Pharmacopoeia, Appendix XII B . HMSO, London, (2001).
   Google Scholar
• RC Qing, GC Han, CK Dong, and JL Beom. (2004). Release behavior and photo image of nifedipine tablet coated with high viscosity grade hydroxypropyl methylcellulose: effect of coating conditions. Int J Pharm. 274 (1–2):107–117.
   PubMedGoogle Scholar
• H Goebell, U Klotz, B Nehlsen, and P. Layer. (1993). Oroileal transit of slow release 5-aminosalicylic acid. Gut. 34 (5):669–675.
   PubMedGoogle Scholar
• PH Layer, H Goebell, J Keller, A Dignass, and U. Klotz. (1995). Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 108 (5):1427–1433.
   PubMedGoogle Scholar
• WJ Sandborn, and SB Hanauer. (2003). Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 17 (1):29–42.
   PubMedGoogle Scholar
• TCDZ Fatmanur, F AcartuSR, T Sevgi, OZ Konus, and A. Boyunag. (2004). In-vitro and in-vivo evaluation of mesalazine–guar gum matrix tablets for colonic drug delivery. J Drug Targeting. 12 (2):105–112.
   PubMedGoogle Scholar
• DD Wirth, SW Baertschi, and RA Johnson. (1998). Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci. 87 (1):31–39.
   PubMedGoogle Scholar
• Handbook of Pharmaceutical Excipients RC Rowe, PJ Sheskey, and PJ Weller. Pharmaceutical Press, London, (2003).
   Google Scholar
• GS Banker, and NR Anderson. Tablets. eds The Theory and Practice of Industrial Pharmacy L Lachman, HA Liberman, and JL Kanig. Varghese Publishing House, MumbaiIndia, (1987)293–345.
   Google Scholar
• Physical Pharmacy: Physical Chemical Principles in Pharmaceutical Sciences A Martin. Lippincott Williams & Wilkins, BaltimoreMD, (2001).
   Google Scholar
• B Haeberlin, and DR Friend. Anatomy and physiology of the gastrointestinal tract: implications for colonic drug delivery. ed Oral Colon-Specific Drug Delivery D.R. Friend. CRC Press, Boca RatonFL, (1992)1–44.
   Google Scholar
• M Ashord, JT Fell, D Attwood, and PJ Woodhead. (1993). An in vitro investigation into the suitability of pH dependent polymers for colon targeting. Int J Pharm. 91 (2–3):241–245.
   Google Scholar